Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_left">Antigen</td><td class="align_center">Cancer</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left">CD44v7/8</td><td class="align_center">Cervical carcinoma</td></tr><tr><td class="align_left">DNAM-1</td><td class="align_center">Prostate carcinoma</td></tr><tr><td class="align_left">EGP-40</td><td class="align_center">Colorectal cancer</td></tr><tr><td class="align_left">EpCAM</td><td class="align_center">Prostate cancer</td></tr><tr><td class="align_left">FBP</td><td class="align_center">Ovarian cancer</td></tr><tr><td class="align_left">FR</td><td class="align_center">Rhabdomyosarcoma</td></tr><tr><td class="align_left">GD3</td><td class="align_center">Melanoma</td></tr><tr><td class="align_left">VEGFR2</td><td class="align_center">Tumor neovasculature</td></tr><tr><td class="align_left">LMP-1</td><td class="align_center">PVR and nectin-2 expressing solid tumors</td></tr><tr><td class="align_left">MUC1</td><td class="align_center">Breast, ovary</td></tr><tr><td class="align_left">PSCA</td><td class="align_center">Melanoma, synovial cell sarcoma</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td>DNAM-1: DNAX accessory molecule-1; EGP-40: epithelial glycoprotein-40; EpCAM: epithelial cell adhesion molecule; FBP: folate-binding protein; LMP-1: latent membrane protein 1; MUC1: mucin 1; PSCA: prostate stem cell antigen.<br/></td></tr></table>

Potential solid tumor targets for CART cell-based therapy.

Journal of Immunology Research

tab2

Table 2

Table 2: Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects 